Study,Year,Data source,ID: CRS,Char: Methods,Char: Participants,Char: Interventions,Char: Outcomes,Char: Author declarations of interest,Char: Study funding source,Char: Notes
Andrews 1999,1999,PUB,26717820,"<p>Study type: Cluster RCT</p><p>Study registration: Not reported</p><p>Setting: USA, Dental practice</p><p>Study dates: Not reported</p><p>Recruitment method: Letters to dental practices and presentations at local dental societies.</p>","<p>Participants: Dental hygiene patients (N = 633, Avg. age = 36.2, 100% Male)</p><p>Smokeless tobacco product: Chewing tobacco and Snuff</p><p>Proportion using combustible tobacco: 0.7%</p><p>Proportion using products containing areca or betel: Not reported</p>","<p>Intervention 1: Usual dental hygiene visit.&nbsp;</p><p>Provider: Dental hygienist.</p><p>Duration and intensity of support: 1 face-to-face session, average 60 minutes.</p><p>Pharmacotherapy: None</p><p>&nbsp;</p><p>Intervention 2: Counselling for dental patients to quit using tobacco, using a 7 component protocol.</p><p>Provider: Dentists and dental hygienists.</p><p>Duration and intensity of support: 1 face-to-face session, average 60 minutes; phone-based contact within 2 weeks of visit to ask if they had read the materials, looked at the video, and either quit or is now willing to set a quit date.</p><p>Pharmacotherapy: None</p>",<p>Definition of abstinence: Sustained</p><p>Longest follow-up: 12 months</p><p>Biochemical validation: Not done</p>,<p>Not reported</p>,"<p>Preparation of the manuscript was supported in part by Grant #1 RO1 HL48768 from the National Heart, Lung, and Blood Institute.</p>",
Boyle 2004,2004,PUB,26717824,"<p>Study type: RCT</p><p>Study registration: Not reported</p><p>Setting: USA, Community</p><p>Study dates: Not reported</p><p>Recruitment method: Advertisements in local radio and newsletters.</p>","<p>Participants: Community residents (N = 221, Avg. age = 35.7 years, 100% Male)</p><p>Smokeless tobacco product: Chewing tobacco or Moist snuff</p><p>Proportion using combustible tobacco: 0%</p><p>Proportion using products containing areca or betel: 0%</p>",<p>Intervention 1: Smokeless tobacco self-help manual sent through post.&nbsp;</p><p>Provider: N/A</p><p>Duration and intensity of support: N/A</p><p>Pharmacotherapy: None</p><p>&nbsp;</p><p>Intervention 2: Smokeless tobacco self-help manual with phone-based counselling.&nbsp;</p><p>Provider: Trained tobacco cessation counsellors.</p><p>Duration and intensity of support: Up to 4 treatment calls designed to assist participants in making a quit attempt. &nbsp;</p><p>Pharmacotherapy: None</p>,<p>Definition of abstinence: 7 day point prevalence</p><p>Longest follow-up: 6 months</p><p>Biochemical validation: Not done</p>,<p>Not reported</p>,<p>Public Health Service Grant CA-74025 from the National Cancer Institute.</p>,
Boyle 2008,2008,PUB,26717826,"<p>Study type: RCT</p><p>Study registration: Not reported</p><p>Setting: USA, Community</p><p>Study dates: 2005-2006</p><p>Recruitment method: Advertisements in local radio and newspapers, mailings to state and local health departments, large employers, and dental hygienists.</p>","<p>Participants: Adults, community residents (N = 406, Avg. age = 39.9 years, 1.7% Female)</p><p>Smokeless tobacco product: Chewing tobacco or Snuff</p><p>Proportion using combustible tobacco: 6.2%</p><p>Proportion using products containing areca or betel: 0%</p>","<p>Intervention 1: Manual-only - 'Enough Snuff: A Guide for Quitting Smokeless Tobacco', a self-help guide sent through post.&nbsp;</p><p>Provider: N/A</p><p>Duration and intensity of support: N/A</p><p>Pharmacotherapy: None</p><p>&nbsp;</p><p>Intervention 2: Self-help manual ('Enough Snuff: A Guide for Quitting Smokeless Tobacco') with phone-based counselling.&nbsp;</p><p>Provider: Trained tobacco cessation counsellors.</p><p>Duration and intensity of support: &nbsp;Up to 4 treatment calls designed to assist participants in making a quit attempt, each lasting 10-30 minutes.&nbsp;</p><p>Pharmacotherapy: None</p>",<p>Definition of abstinence: 7 day point prevalence and sustained</p><p>Longest follow-up: 6 months</p><p>Biochemical validation: Not done</p>,<p>None of the authors have any competing interests with ClearWay Minnesota.</p>,"<p>This research was performed at HealthPartners Research Foundation, Bloomington, Minnesota. Any public dissemination of information relating to the grant was made possible by Grant RC-2004-0010 from ClearWay Minnesota.&nbsp;</p>",
Cigrang 2002,2002,PUB,26717829,"<p>Study type: RCT</p><p>Study registration: Not reported</p><p>Setting: USA, Military</p><p>Study dates: 1999-2000</p><p>Recruitment method: Active-duty military personnel proactively contacted by phone after preventive health screening visit.</p>","<p>Participants: Active-duty military personnel (N = 60, Avg. age = 31 years, 100% Male)</p><p>Smokeless tobacco product: Not reported</p><p>Proportion using combustible tobacco: Not reported</p><p>Proportion using products containing areca or betel: 0%</p>","<p>Intervention 1: Usual care - All screened personnel who reported current use of ST were encouraged to consider quitting and provided information on how to sign up to attend an 8-week tobacco cessation class.</p><p>Provider: N/A</p><p>Duration and intensity of support: N/A</p><p>Pharmacotherapy: None</p><p>&nbsp;</p><p>Intervention 2: Comprehensive Enough Snuff manual for quitting ST and an Enough Snuff video sent through post with phone-based support.</p><p>Provider: Unclear</p><p>Duration and intensity of support: 2 supportive phone calls, lasting 10 minutes.</p><p>Pharmacotherapy: None</p>",<p>Definition of abstinence: 7 day point prevalence</p><p>Longest follow-up: 6 months</p><p>Biochemical validation: Not done</p>,<p>Not reported</p>,<p>Not reported</p>,
Cummings 1996,1996,PUB,26717831,"<p>Study type: Cluster RCT</p><p>Study registration: Not reported</p><p>Setting: USA, Workplace</p><p>Study dates: 1990-1993</p><p>Recruitment method: Employees at participating workplaces.</p>","<p>Participants: Employees at participating workplaces (N = 1196, Avg. age = 36 years, 100% Male)</p><p>Smokeless tobacco product: Not reported</p><p>Proportion using combustible tobacco: 19.0%</p><p>Proportion using products containing areca or betel: Not reported</p>","<p>Intervention 1: Minimal intervention with standard health risk information, e.g. brochures, posted to workplace.&nbsp;</p><p>Provider: N/A</p><p>Duration and intensity of support: Regular, scheduled mailing of print material - 10 mailings; 4 in year 1 and 6 in year 2.</p><p>Pharmacotherapy: None</p><p>&nbsp;</p><p>Intervention 2: Stage‐matched ST information (brochures, videos, posters), modules on specific risk factors, organisational interventions aimed at environmental and policy change, e.g. restrictive tobacco policies.&nbsp;</p><p>Provider: Employee advisory board in consultation with project staff.</p><p>Duration and intensity of support: Not reported</p><p>Pharmacotherapy: None</p>",<p>Definition of abstinence: Point prevalence</p><p>Longest follow-up: 24 months</p><p>Biochemical validation: Not done</p>,<p>Not reported</p>,<p>USA National Cancer Institute.</p>,
Dale 2002,2002,PUB,26717833,"<p>Study type: RCT</p><p>Study registration: Not reported</p><p>Setting: USA, Health centre</p><p>Study dates: Not reported</p><p>Recruitment method: Local advertisements and press releases.</p>","<p>Participants: Adults, ST users (N = 68, Avg. age = 35.8 years in intervention and 37.1 years in control, 1.5% Female)&nbsp;</p><p>Smokeless tobacco product: Chewing tobacco or Snuff</p><p>Proportion using combustible tobacco: Not reported</p><p>Proportion using products containing areca or betel: Not reported</p>","<p>Intervention 1: 10-minute behavioural intervention at each visit with placebo.</p><p>Provider: Study assistant</p><p>Duration and intensity of support: 10 minutes at each visit.</p><p>Pharmacotherapy: 12 weeks placebo (one tablet once a day for 3 days, then one twice per day).</p><p>&nbsp;</p><p>Intervention 2: 10-minute behavioural intervention at each visit with Bupropion.</p><p>Provider: Study assistant</p><p>Duration and intensity of support: 10 minutes at each visit.</p><p>Pharmacotherapy: 12 weeks Bupropion SR 150mg by mouth (one tablet once a day for 3 days, then one twice per day).</p>",<p>Definition of abstinence: 7 day point prevalence and sustained</p><p>Longest follow-up: 24 weeks</p><p>Biochemical validation: &nbsp;Urine cotinine &lt;50 ng/ml</p>,<p>Not reported</p>,<p>Not reported</p>,
Dale 2007,2007,PUB,26717835,"<p>Study type: RCT</p><p>Study registration: Not reported</p><p>Setting: USA, Health centre</p><p>Study dates: Not reported</p><p>Recruitment method: Local advertisements and press releases.</p>","<p>Participants: Adults, ST users (N = 225, Avg. age = 38.1 years, 100% Male)</p><p>Smokeless tobacco product: Chewing tobacco or Snuff</p><p>Proportion using combustible tobacco: 1.3%</p><p>Proportion using products containing areca or betel: 0%</p>","<p>Intervention 1: 1-to-1 counselling using manual topics with placebo medication.</p><p>Provider: Study assistant</p><p>Duration and intensity of support: 15 sessions (13 face-to-face, 2 phone-based) over 52 weeks.</p><p>Pharmacotherapy: 12 weeks placebo medication.</p><p>&nbsp;</p><p>Intervention 2: 1-to-1 counselling using manual topics with Bupropion medication.</p><p>Provider: Study assistant</p><p>Duration and intensity of support: 15 sessions (13 face-to-face, 2 phone-based) over 52 weeks.</p><p>Pharmacotherapy: 12 weeks Bupropion SR (150 mg), titrated one tablet by mouth.</p>",<p>Definition of abstinence: 7 day point prevalence and sustained</p><p>Longest follow-up: 52 weeks</p><p>Biochemical validation: Urine cotinine &lt;50 ng/ml</p>,<p>The authors have no conflicts of interest to report.</p>,<p>National Cancer Institute (Grant R01 90884).</p>,
Danaher 2013,2013,PUB,26717840,"<p>Study type: RCT</p><p>Study registration: NCT00680615</p><p>Setting: USA and Canada, Community (Web-based)</p><p>Study dates: 2008-2011</p><p>Recruitment method: Online channels (e.g. Google AdWords AdBrite, YouTube, Facebook), advertisements in newspapers and radio, outreach efforts to professionals in tobacco control agencies and schools.</p>","<p>Participants: 14-25 year-olds, community residents (N = 1716, Avg. age = 20.8 years, 3.5% Female)</p><p>Smokeless tobacco product: Chewing tobacco, Snuff or US 'dip'</p><p>Proportion using combustible tobacco: 13.5%</p><p>Proportion using products containing areca or betel: 0%</p>","<p>Intervention 1: Basic web-based intervention, provided an online ST cessation guide in static text. It included an online version of the 'Enough Snuff' pocket guide for quitting ST.</p><p>Provider: Web-based.</p><p>Duration and intensity of support: N/A</p><p>Pharmacotherapy: None</p><p>&nbsp;</p><p>Intervention 2: The Enhanced web-based condition, provided best-practices ST cessation content using interactive and multimedia features.</p><p>Provider: Web-based.</p><p>Duration and intensity of support: Intervention 'driven' by participant engagement</p><p>Pharmacotherapy: None</p>",<p>Definition of abstinence: 7 day point prevalence&nbsp;</p><p>Longest follow-up: 6 months</p><p>Biochemical validation: Not done</p>,<p>None</p>,<p>National Cancer Institute at the National Institutes of Health (R01-CA118575).</p>,
Danaher 2015a,2015,PUB,26717844,"<p>Study type: Factorial RCT (2x2)</p><p>Study registration: NCT00820495</p><p>Setting: USA, Community (Web-based)</p><p>Study dates: 2008-2011</p><p>Recruitment method: Online marketing campaign and marketing website.</p>","<p>Participants: 25 years and older, community residents (N = 1683, Avg. age = 37.9 years, 2.5% Female)</p><p>Smokeless tobacco product: Chewing tobacco, Snuff, Snus</p><p>Proportion using combustible tobacco: 8.0%</p><p>Proportion using products containing areca or betel: 0%</p>","<p>Intervention 1: Self-help material, sent through post.</p><p>Provider: N/A</p><p>Duration and intensity of support: N/A</p><p>Pharmacotherapy: None.</p><p>&nbsp;</p><p>Intervention 2: Self-help material, sent through post + Fully-automated, tailored, interactive enhanced web-based smokeless tobacco cessation intervention used in the ChewFree trial.</p><p>Provider: Web-based</p><p>Duration and intensity of support: N/A&nbsp;</p><p>Pharmacotherapy: None.</p><p>&nbsp;</p><p>Intervention 3: Self-help material, sent through post + Proactive calls from the California Tobacco Chewers’ Helpline.</p><p>Provider: Trained counsellors.</p><p>Duration and intensity of support: Up to 4 follow-up calls to review the personalized plan, discuss relapse prevention, and encourage another quit attempt if needed.</p><p>Pharmacotherapy: None</p><p>&nbsp;</p><p>Intervention 4: Self-help material, sent through post + Fully-automated, tailored, interactive enhanced web-based smokeless tobacco cessation intervention used in the ChewFree trial + Proactive calls from the California Tobacco Chewers’ Helpline.</p><p>Provider: Web-based and trained counsellors.</p><p>Duration and intensity of support: Up to 4 follow-up calls to review the personalized plan, discuss relapse prevention, and encourage another quit attempt if needed.</p><p>Pharmacotherapy: None</p>",<p>Definition of abstinence: 7 day point prevalence</p><p>Longest follow-up: 6 months</p><p>Biochemical validation: Not done</p>,<p>None declared</p>,<p>National Cancer Institute of the National Institutes of Health (R01-CA084225).</p>,
Danaher 2015b,2015,PUB,26717848,"<p>Study type: RCT</p><p>Study registration: Not reported</p><p>Setting: USA, Community (Web-based)</p><p>Study dates: 2013</p><p>Recruitment method: Nationwide online marketing.</p>","<p>Participants: Adults, community residents (N = 407, Avg. age = 35.2 years, 2.5% Female)</p><p>Smokeless tobacco product: Chewing tobacco, Snuff, Snus</p><p>Proportion using combustible tobacco: 7.1%</p><p>Proportion using products containing areca or betel: 0%</p>","<p>Intervention 1: MyLastDip, interactive web-based intervention.</p><p>Provider: Web-based.</p><p>Duration and intensity of support: Program content grouped according to three sequential frames: preparing to quit, quitting, and staying quit. If a participant reported a lapse, then the program would provide tailored content on lessons learned and starting over (“retooling”).</p><p>Pharmacotherapy: None</p><p>&nbsp;</p><p>Intervention 2: MyLastDip, interactive web-based intervention with NRT.</p><p>Provider: Web-based.</p><p>Duration and intensity of support: N/A&nbsp;</p><p>Pharmacotherapy: 2 boxes of Nicorette® Lozenges (4mg; 108 lozenges/box) mailed; NRT for 12 weeks, could ask for up to 3 months.</p>",<p>Definition of abstinence: 7 day point prevalence&nbsp;</p><p>Longest follow-up: 6 months</p><p>Biochemical validation: Not done</p>,"<p>Dr. Ebbert has received consulting fees from GlaxoSmithKline and has received research support from Pfizer, Orexigen and JHP outside of the current study. GlaxoSmithKline provided the nicotine lozenges for the study but had no role in the conduct of the study (data collection, management, analysis, and interpretation), in the preparation, review, approval of the manuscript, or in the decision to submit the manuscript for publication.</p>",<p>National Cancer Institute of the National Institutes of Health (R01-CA142952).</p>,
Ebbert 2007,2007,PUB,26717850,"<p>Study type: RCT</p><p>Study registration: Not reported</p><p>Setting: USA, Health centre</p><p>Study dates: 2003-2005</p><p>Recruitment method: Local advertisements and press releases.</p>","<p>Participants: Adults, ST users (N = 42, Avg. age = 34.0-38.0 years, 100% Male)</p><p>Smokeless tobacco product: Snuff</p><p>Proportion using combustible tobacco: 0%</p><p>Proportion using products containing areca or betel: 0%</p>","<p>Intervention 1: Placebo patches with electronic diary to record data, e.g. mood, withdrawal, and adverse events. 3-day in-patient stay, followed by out-patient treatment and follow-up.</p><p>Provider: N/A</p><p>Duration and intensity of support: N/A</p><p>Pharmacotherapy: Placebo patches, 8 weeks with taper. Subjects wore 3 patches in weeks 0–4, two in weeks 5-6, one in weeks 7-8.</p><p>&nbsp;</p><p>Intervention 2: Nicotine patches with electronic diary to record data.</p><p>Provider: N/A</p><p>Duration and intensity of support: N/A&nbsp;</p><p>Pharmacotherapy: Nicotine patches (21 mg/day), 8 weeks with taper. Subjects wore 3 patches in weeks 0–4, two in weeks 5-6, one in weeks 7-8.</p><p>&nbsp;</p><p>Intervention 3: Nicotine patches with electronic diary to record data.</p><p>Provider: N/A</p><p>Duration and intensity of support: N/A&nbsp;</p><p>Pharmacotherapy: Nicotine patches (42 mg/day), 8 weeks with taper. Subjects wore 3 patches in weeks 0–4, two in weeks 5-6, one in weeks 7-8.</p><p>&nbsp;</p><p>Intervention 4: Nicotine patches with electronic diary to record data.</p><p>Provider: N/A</p><p>Duration and intensity of support: N/A&nbsp;</p><p>Pharmacotherapy: Nicotine patches (63 mg/day), 8 weeks with taper. Subjects wore 3 patches in weeks 0–4, two in weeks 5-6, one in weeks 7-8.</p>",<p>Definition of abstinence: 7 day point prevalence and sustained</p><p>Longest follow-up: 6 months</p><p>Biochemical validation: Urine anabasine &lt;2 ng/ml&nbsp;</p>,<p>Not reported</p>,<p>National Cancer Institute (Grant R01 CA96881).</p>,
Ebbert 2009,2009,PUB,26717853,"<p>Study type: RCT</p><p>Study registration: Not reported</p><p>Setting: USA, Health centre</p><p>Study dates: 2007-2008</p><p>Recruitment method: Local advertisements and press releases.</p>","<p>Participants: Adults, ST users (N = 270, Avg. age = 36.5 years, 2.2% Female)</p><p>Smokeless tobacco product: Chewing tobacco or Snuff</p><p>Proportion using combustible tobacco: 10.7%</p><p>Proportion using products containing areca or betel: Not reported</p>","<p>Intervention 1: Brief behavioural support with placebo lozenges.&nbsp;</p><p>Provider: Not reported</p><p>Duration and intensity of support: 1 face-to-face session, 10 mins length.&nbsp;</p><p>Pharmacotherapy: Placebo lozenges for 12 weeks, tapered use.</p><p>&nbsp;</p><p>Intervention 2: Brief behavioural support with nicotine lozenges.&nbsp;</p><p>Provider: Not reported</p><p>Duration and intensity of support: 1 face-to-face session, 10 mins length.&nbsp;</p><p>Pharmacotherapy: nicotine lozenges (4 mg) for 12 weeks, tapered use.</p>",<p>Definition of abstinence: 7 day point prevalence</p><p>Longest follow-up: 24 weeks</p><p>Biochemical validation: Urine anabasine &lt; 2 ng/ml&nbsp;</p>,<p>None declared</p>,<p>National Cancer Institute Award (CA121165).</p>,
Ebbert 2010,2010,PUB,26717856,"<p>Study type: RCT</p><p>Study registration: Not reported</p><p>Setting: USA, Health centre</p><p>Study dates: 2008-2009</p><p>Recruitment method: Local advertisements and press releases.</p>","<p>Participants: Adults, ST users (N = 60, Avg. age = placebo: 43.6 years in intervention and 42.4 years in control, 100% Male)</p><p>Smokeless tobacco product: Snuff</p><p>Proportion using combustible tobacco: 7.0%</p><p>Proportion using products containing areca or betel: Not reported</p>","<p>Intervention 1: The assisted self-help intervention (ASH), including a self-help quitting guide (Severson, 1999) and telephone counseling with placebo.&nbsp;</p><p>Provider: Study assistants</p><p>Duration and intensity of support: Counselling calls lasted 5-15 minutes.&nbsp;</p><p>Pharmacotherapy: 12 weeks placebo.</p><p>&nbsp;</p><p>Intervention 2: The assisted self-help intervention (ASH), including a self-help quitting guide (Severson, 1999) and telephone counseling with nicotine lozenges.</p><p>Provider: Study assistants</p><p>Duration and intensity of support: Counselling calls lasted 5-15 minutes.&nbsp;</p><p>Pharmacotherapy: 12 weeks nicotine lozenges (4 mg).</p>",<p>Definition of abstinence: 7 day point prevalence for all tobacco and sustained for ST</p><p>Longest follow-up: 6 months</p><p>Biochemical validation: Not done&nbsp;</p>,<p>None to declare.</p>,<p>National Cancer Institute Award (CA 121165).</p>,
Ebbert 2011,2011,PUB,26717858,"<p>Study type: RCT</p><p>Study registration: Not reported</p><p>Setting: USA, Health centre</p><p>Study dates: 2009-2011</p><p>Recruitment method: Not reported</p>","<p>Participants: Clinic outpatients (N = 76, Avg. age = 40.7 years in intervention and 41.0 years in control, 100% Male)</p><p>Smokeless tobacco product: ST cans/pouches</p><p>Proportion using combustible tobacco: 6.6%</p><p>Proportion using products containing areca or betel: 0%</p>","<p>Intervention 1: Standardised behavioural counselling and treatment manual with placebo tablets.</p><p>Provider: Study assistants</p><p>Duration and intensity of support: 4 x 10 minutes face-to-face sessions.</p><p>Pharmacotherapy: 12 weeks placebo.</p><p>&nbsp;</p><p>Intervention 2: Standardised behavioural counselling and treatment manual with Varenicline.</p><p>Provider: Study assistants</p><p>Duration and intensity of support: 4 x 10 minutes face-to-face sessions.</p><p>Pharmacotherapy: 12 weeks Varenicline, 1 mg twice daily.</p>",<p>Definition of abstinence: 7 day point prevalence and sustained</p><p>Longest follow-up: 6 months</p><p>Biochemical validation: Urine cotinine &lt;50 ng/ml</p>,<p>None declared.</p>,<p>National Cancer Institute (Grant CA132621).</p>,
Ebbert 2013a,2013,PUB,26717860,"<p>Study type: RCT</p><p>Study registration: Not reported</p><p>Setting: USA, Community</p><p>Study dates: 2010-2012</p><p>Recruitment method: Marketing campaign.</p>","<p>Participants: Community residents (N = 81, Avg. age = 37.8 years in intervention and 37.5 years in control, 3.8% Female)</p><p>Smokeless tobacco product: Chewing tobacco and Snuff</p><p>Proportion using combustible tobacco: 8.6%</p><p>Proportion using products containing areca or betel: 0%</p>",<p>Intervention 1: Face-to-face and written guidance on ST reduction and diary with tobacco-free snuff.</p><p>Provider: Not reported</p><p>Duration and intensity of support: 8 weekly and 2 fortnightly face-to-face sessions over 12 weeks.</p><p>Pharmacotherapy: Upto 12 weeks tobacco-free snuff.</p><p>&nbsp;</p><p>Intervention 2: Face-to-face and written guidance on ST reduction and diary with nicotine lozenges.</p><p>Provider: Not reported</p><p>Duration and intensity of support: 8 weekly and 2 fortnightly face-to-face sessions over 12 weeks.</p><p>Pharmacotherapy: Upto 12 weeks nicotine lozenges (4mg).</p>,<p>Definition of abstinence: Not reported</p><p>Longest follow-up: 6 months</p><p>Biochemical validation: Urine anabasine and anatabine &lt;2 ng/ml</p>,"<p>Dr. Jon O. Ebbert has received consulting fees from GlaxoSmithKline, manufacturer of the nicotine lozenge.</p>","<p>The clinical trial was supported by the National Institutes of Health (R01 CA121165 to Jon O. Ebbert, MD). Chemical analyses were performed by the Clinical Pharmacology Laboratory at the University of California, San Francisco with instrumentation and analytical chemistry support from the National Institutes of Health (P30 DA012393 &amp; S10 RR026437 to Neal L. Benowitz, MD).</p>",
Ebbert 2013b,2013,PUB,26717862,"<p>Study type: RCT</p><p>Study registration: NCT00939029</p><p>Setting: USA, Health centre</p><p>Study dates: 2010-2012</p><p>Recruitment method: Local advertisements and press releases.</p>","<p>Participants: Adults, Community residents (N = 52, Avg. age = 39.2 years in intervention and 35.3 years in control, 100% Male)</p><p>Smokeless tobacco product: ST cans/pouches</p><p>Proportion using combustible tobacco: 0%</p><p>Proportion using products containing areca or betel: Not reported</p>","<p>Intervention 1: Counselling sessions and treatment manual with placebo patches.</p><p>Provider: Research staff</p><p>Duration and intensity of support: 4 face-to-face sessions, 10-15 minutes length, over 8 weeks.</p><p>Pharmacotherapy: 2 placebo NRT patches (Weeks 1-6), 1 placebo patch (Weeks 7-8).</p><p>&nbsp;</p><p>Intervention 2: Counselling sessions and treatment manual with NRT patches.</p><p>Provider: Research staff</p><p>Duration and intensity of support: 4 face-to-face sessions, 10-15 minutes length, over 8 weeks.</p><p>Pharmacotherapy: 2 high-dose (42mg/day) nicotine patches (Weeks 1-6), 1 high-dose (21mg/day) nicotine patch &nbsp;(Weeks 7-8).</p>",<p>Definition of abstinence: 7 day point prevalence and sustained</p><p>Longest follow-up: 6 months</p><p>Biochemical validation: Urine anabasine &lt;2 ng/ml</p>,<p>JOE reports a grant from NIH during the conduct of the study. JOE also received grants from Pfizer and personal fees from GlaxoSmithKline for studies not related to the study reported. RDH reports grants from NIH and Pfizer outside the submitted work. ITC and DRS report no conflicts of interest.</p>,<p>National Institutes of Health (Grant CA 140125).</p>,
Fagerstrom 2010,2010,PUB,26717865,"<p>Study type: RCT</p><p>Study registration: NCT00717093</p><p>Setting: Norway and Sweden, Health centre</p><p>Study dates: 2008-2010</p><p>Recruitment method: Newspaper advertisements.&nbsp;</p>","<p>Participants: Adults, ST users (N = 431, Avg. age = 43.9 years, 10% Female)</p><p>Smokeless tobacco product: Snus</p><p>Proportion using combustible tobacco: 0%</p><p>Proportion using products containing areca or betel: 0%</p>","<p>Intervention 1: Brief behavioural support ('tips &amp; hints') with placebo tablets.</p><p>Provider: Investigator led, otherwise not stated.</p><p>Duration and intensity of support: Not reported</p><p>Pharmacotherapy: Placebo tablets - 12 weeks, Week 1 titrated dose, then daily 1 mg to Week 12.</p><p>&nbsp;</p><p>Intervention 2: Brief behavioural support ('tips &amp; hints') with Varenicline.</p><p>Provider: Investigator led, otherwise not stated.</p><p>Duration and intensity of support: Not reported</p><p>Pharmacotherapy: Varenicline tablets - 12 weeks, Week 1 titrated dose, then 1 mg twice daily to Week 12.</p>",<p>Definition of abstinence: Sustained</p><p>Longest follow-up: 26 weeks</p><p>Biochemical validation: Salivary cotinine &gt;15 ng/ml</p>,"<p>All authors have completed the Unified Competing Interest form at www.icmje.org/coi_discolsure.pdf (available on request from the corresponding author) and declare: the institutions of ST and HG received support from Pfizer for the clinical trial; KF, ST, and HG have specified relationships with Pfizer, who might have an interest in the submitted work; MMet and MMes are employees of, and stockholders in, Pfizer.</p>","<p>This work was supported by Pfizer. KF, HG, and ST did not receive any financial support with respect to the writing or development of this manuscript. Role of the study sponsor: Pfizer, the study sponsor, was involved in study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.</p>",
Gansky 2002,2002,PUB,26717871,"<p>Study type: Cluster RCT</p><p>Study registration: Not reported</p><p>Setting: USA, High school (Rural)</p><p>Study dates: 1996-1998</p><p>Recruitment method: School principals contacted to send consent forms to all parents of baseball athletes.</p>","<p>Participants: High-school baseball playing students (N = 307, Avg. age = Not reported, 100% Male)</p><p>Smokeless tobacco product: Chewing tobacco or US 'dip'</p><p>Proportion using combustible tobacco: 11.0%</p><p>Proportion using products containing areca or betel: 0%</p>","<p>Intervention 1: No treatment.</p><p>Provider: N/A</p><p>Duration and intensity of support: N/A</p><p>Pharmacotherapy: None</p><p>&nbsp;</p><p>Intervention 2: Peer-led session including a presentration, video, and discussion; oral cancer screening and brief cessation counselling, followed by follow-up call on quit day.</p><p>Provider: Peers, unclear for screening and counselling.</p><p>Duration and intensity of support: 1x1 hour face-to-face peer session; 15 min oral screening and breif counselling; 5-10 minute follow-up call.</p><p>Pharmacotherapy: None</p>",<p>Definition of abstinence: Sustained</p><p>Longest follow-up: 24 months</p><p>Biochemical validation: Not done</p>,<p>Not reported</p>,"<p>Tobacco Surtax Fund of the State of California (Grant 4RT-0068) through the Tobacco-Related Disease Research Program of the University California, and the National Cancer Institute (Grant CA 67654).</p>",
Gansky 2005,2005,PUB,26717875,"<p>Study type: Cluster RCT</p><p>Study registration: Not reported</p><p>Setting: USA, College</p><p>Study dates: 1999-2000</p><p>Recruitment method: Contacting certified athletic trainers (ATCs) at colleges.</p>","<p>Participants: Collegiate baseball athletes (N = 637, Avg. age = Not reported; 100% Male)</p><p>Smokeless tobacco product: Chewing tobacco, Snuff, Spit</p><p>Proportion using combustible tobacco: 66.0%</p><p>Proportion using products containing areca or betel: Not reported</p>","<p>Intervention 1: Usual anti-tobacco education offered at their colleges.</p><p>Provider: Not reported</p><p>Duration and intensity of support: Not reported</p><p>Pharmacotherapy: None</p><p>&nbsp;</p><p>Intervention 2: Oral cancer screening with feedback and brief<br>counselling, athletic trainer follow-up support, and a peer-led educational baseball team meeting.</p><p>Provider: Dentist or dental hygienist for oral screening and counselling, certified athletic trainer for follow-up support, and peer leader for the education session.</p><p>Duration and intensity of support: 1 oral screening and counselling session (10-15 min); trainer follow-up on scheduled quit date and in 3 group booster<br>sessions scheduled 1 week apart - trainers referred athletes wishing more intensive support to tobacco cessation counselors; 1 interactive educational meeting (50-60 min); all face-to-face sessions.</p><p>Pharmacotherapy: None</p>",<p>Definition of abstinence: 30 day point prevalence</p><p>Longest follow-up: 12 months</p><p>Biochemical validation: Not done</p>,<p>Not reported</p>,<p>Tobacco Surtax Fund of the State of California (Grant 4RT-0068) through the Tobacco-Related Disease Research Program of the University of California.&nbsp;</p>,
Hatsukami 1996,1996,PUB,26717878,"<p>Study type: RCT</p><p>Study registration: Not reported</p><p>Setting: USA, Community</p><p>Study dates: Not reported</p><p>Recruitment method: Advertisements in newspapers and university campus.&nbsp;</p>","<p>Participants: Community residents (N = 210, Avg. age = 30.5 years, 100% Male)</p><p>Smokeless tobacco product: ST tins</p><p>Proportion using combustible tobacco: 0%</p><p>Proportion using products containing areca or betel: Not reported</p>","<p>Intervention 1: Minimal contact and treatment manual with placebo gum.</p><p>Provider: Registered nurse</p><p>Duration and intensity of support: 4 inividual face-to-face sessions over 10 weeks, each 15 min.</p><p>Pharmacotherapy: Placebo gum.</p><p>&nbsp;</p><p>Intervention 2: Group behavioural therapy with placebo gum.</p><p>Provider: Trained therapist</p><p>Duration and intensity of support: 8 group face-to-face sessions over 10 weeks, each 45-60 min.</p><p>Pharmacotherapy: Placebo gum.</p><p>&nbsp;</p><p>Intervention 3: Minimal contact and treatment manual with nicotine gum (2mg).&nbsp;</p><p>Provider: Registered nurse</p><p>Duration and intensity of support: 4 inividual face-to-face sessions over 10 weeks, each 15 min.</p><p>Pharmacotherapy: NRT gum (2mg) up to 3 months - at least six pieces of gum each day for a period of 1 month, then tapering.</p><p>&nbsp;</p><p>Intervention 4: Group behavioural therapy with nicotine gum (2mg).&nbsp;</p><p>Provider: Trained therapist</p><p>Duration and intensity of support: 8 group face-to-face sessions over 10 weeks, each 45-60 min.</p><p>Pharmacotherapy: NRT gum (2mg) up to 3 months - at least six pieces of gum each day for a period of 1 month, then tapering.</p>",<p>Definition of abstinence: Not reported</p><p>Longest follow-up: 12 months</p><p>Biochemical validation: Salivary cotinine &lt;20 ng/ml</p>,<p>Not reported</p>,<p>National Institutes of Health (Grant R01 DA0513).</p>,
Hatsukami 2000,2000,PUB,26717880,"<p>Study type: Factorial RCT (2x2)</p><p>Study registration: Not reported</p><p>Setting: USA, Community</p><p>Study dates: Not reported</p><p>Recruitment method: Newspaper advertising</p>","<p>Participants: Community residents (N = 402, Avg. age = 30.8 years, 1.0% Female)</p><p>Smokeless tobacco product: Spit tobacco</p><p>Proportion using combustible tobacco: 0%</p><p>Proportion using products containing areca or betel: Not reported</p>","<p>Intervention 1: Individual counselling and treatment manual, with placebo patch.</p><p>Provider: Trained therapist</p><p>Duration and intensity of support: 8 face-to-face counselling sessions, 10 min long, over 10 weeks.</p><p>Pharmacotherapy: Placebo patch for 10 weeks.</p><p>&nbsp;</p><p>Intervention 2: Individual counselling and treatment manual, with placebo patch and mint snuff.&nbsp;</p><p>Provider: Trained therapist</p><p>Duration and intensity of support: 8 face-to-face counselling sessions, 10 min long, over 10 weeks.</p><p>Pharmacotherapy: Placebo patch and mint snuff (3 tins per week) for 10 weeks.</p><p>&nbsp;</p><p>Intervention 3: Individual counselling and treatment manual, with NRT patch.&nbsp;</p><p>Provider: Trained therapist</p><p>Duration and intensity of support: 8 face-to-face counselling sessions, 10 min long, over 10 weeks.</p><p>Pharmacotherapy: NRT patch for 10 weeks.</p><p>&nbsp;</p><p>Intervention 4: Individual counselling and treatment manual, with NRT patch and mint snuff.&nbsp;</p><p>Provider: Trained therapist</p><p>Duration and intensity of support: 8 face-to-face counselling sessions, 10 min long, over 10 weeks.</p><p>Pharmacotherapy: NRT patch and mint snuff (3 tins per week) for 10 weeks.</p>",<p>Definition of abstinence: Unclear</p><p>Longest follow-up: 62 weeks</p><p>Biochemical validation: &nbsp;Urine anabasine or anatabine &lt;2 ng/ml and cotinine &lt;15 ng/ml</p>,<p>Pharmaceuticals supplied by SmithKline Beecham and Oregon Mint Snuff.&nbsp;</p>,<p>National Institutes of Health (Grant R01 DA0513).</p>,
Howard-Pitney 1999,1999,PUB,26717882,"<p>Study type: RCT</p><p>Study registration: Not reported</p><p>Setting: USA, Community</p><p>Study dates: Not reported</p><p>Recruitment method: Television, radio, and newspaper advertisements, recruitment brochures and flyers at community locations, and word of mouth.</p>","<p>Participants: Adults, community residents (N = 410, Avg. age = 36.3 years in intervention and 34.7 years in control, 1.0% Female)</p><p>Smokeless tobacco product: Chewing tobacco or Snuff</p><p>Proportion using combustible tobacco: 7.0% in intervention and 3.0% in control</p><p>Proportion using products containing areca or betel: Not reported</p>","<p>Intervention 1: Behavioural treatment included meeting with a pharmacist, written self-help materials, and telephone support.&nbsp;</p><p>Provider: Pharmacist</p><p>Duration and intensity of support: 2 pharmacy visits, 2 support calls and self-help materials.</p><p>Pharmacotherapy: Placebo patch for 6 weeks.</p><p>&nbsp;</p><p>Intervention 2: Behavioural treatment included meeting with a pharmacist, written self-help materials, and telephone support.&nbsp;</p><p>Provider: Pharmacist</p><p>Duration and intensity of support: 2 pharmacy visits, 2 support calls and self-help materials.</p><p>Pharmacotherapy: NRT patch for 6 weeks (15mg patches).</p>",<p>Definition of abstinence: 7 day point prevalence</p><p>Longest follow-up: 6 months</p><p>Biochemical validation: Salivary cotinine &lt; 20 ng/ml</p>,<p>Not reported</p>,"<p>National Institution of Health Public Health Service Grant R01 CA64285 from the National Cancer Institution and a drug suppply agreement with Phaemacia and Upjohn AB (Helsingborg, Sweden).</p>",
Kumbhalwar 2022,2022,PUB,26717884,"<p>Study type: RCT</p><p>Study registration: Not reported</p><p>Setting: India, Dental practice</p><p>Study dates: Not reported</p><p>Recruitment method: ST users at dental hospital.</p>","<p>Participants: ST users at dental hospital (N = 200, Avg. age = 36.6 years in intervention and 27.2 years in control, &nbsp;Female 12.0% in intervention and 17.0% in control)</p><p>Smokeless tobacco product: Not reported</p><p>Proportion using combustible tobacco: 0%</p><p>Proportion using products containing areca or betel: Not reported</p>","<p>Intervention 1: Brief advice, and provided with a toll-free national tobacco quitline number.</p><p>Provider: Unclear</p><p>Duration and intensity of support: 1 face-to-face session, 5-7 min.</p><p>Pharmacotherapy: None</p><p>&nbsp;</p><p>Intervention 2: Behavioral counseling based on 5 A’s and 5 R’s, and motivational interviewing. After the quit date, the intervention was focused on avoiding relapse</p><p>Provider: Trained tobacco cessation counsellors.</p><p>Duration and intensity of support: Face-to-face counselling session (15-20 min) at baseline with phone-based follow-up.&nbsp;</p><p>Pharmacotherapy: None</p>",<p>Definition of abstinence: Point prevalence</p><p>Longest follow-up: 6 months</p><p>Biochemical validation: Urine cotinine &lt;200 mg/ml</p>,"<p>In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: This project was supported by the Narotam Sekhsaria Foundation (NSF) and received a grant of 30,000/-INR (Grant Number: CORPH19037594326). Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.</p>","<p>This project was supported by the Narotam Sekhsaria Foundation (NSF) and received a grant of 30,000/- INR (Grant Number: CORPH19037594326).</p>",
Mall 2021,2021,PUB,26717886,"<p>Study type: Cluster RCT</p><p>Study registration: Not reported</p><p>Setting: India, Community (Urban slum)</p><p>Study dates: 2018-2019</p><p>Recruitment method: House-to-house visits in selected slums.</p>","<p>Participants: Adults, slum residents (N = 400, Avg. age = 37.7 years, Majority male participants)</p><p>Smokeless tobacco product: Not reported</p><p>Proportion using combustible tobacco: 1.3%</p><p>Proportion using products containing areca or betel: Not reported</p>","<p>Intervention 1: No treatment - Health intervention was given in the control group at the end of the study using the same materials and methods.</p><p>Provider: N/A</p><p>Duration and intensity of support: N/A</p><p>Pharmacotherapy: None</p><p>&nbsp;</p><p>Intervention 2: Two-stage intervention - Frist included health education, role-play, and a detailed plan as to how to quit tobacco. Second included experience sharing of group members in quitting tobacco, withdrawal symptoms, and measures to overcome them.&nbsp;</p><p>Provider: Unclear</p><p>Duration and intensity of support: Session one (face-to-face): 45 minutes, &nbsp;as soon as convenient following baseline data collection. Session two (face-to-face): 30 minutes, 11 months later.&nbsp;</p><p>Pharmacotherapy: None</p>",<p>Definition of abstinence: 7 day point prevalence</p><p>Longest follow-up: 12 months</p><p>Biochemical validation: Not done</p>,<p>There are no conflicts of interest.</p>,<p>Nil</p>,
Noonan 2020,2020,PUB,26717888,"<p>Study type: RCT</p><p>Study registration: Not reported</p><p>Setting: USA, Community (Rural)</p><p>Study dates: Not reported</p><p>Recruitment method: Letters through primary care clinics, and social media.</p>","<p>Participants: Community residents (N = 98, Avg. age = 31.0 years, 1.1% Female)</p><p>Smokeless tobacco product: Chews/dips</p><p>Proportion using combustible tobacco: Not reported</p><p>Proportion using products containing areca or betel: Not reported</p>","<p>Intervention 1: Text-message support.&nbsp;</p><p>Provider: N/A</p><p>Duration and intensity of support: 4 weeks; participants received two messages a day during weeks 1 and 4, and up to three a day during weeks 2 and 3.</p><p>Pharmacotherapy: None</p><p>&nbsp;</p><p>Intervention 2: Text-messages supporting gradual reduction of tobacco. Week 1: participants chew as usual and text “s” every time; Over the next three weeks, reduced by 1/3 each week down to zero use. Those with a baseline mean of 10 or more uses per day offered an extra reduction week. The last day of program was considered the quit date.</p><p>Provider: N/A</p><p>Duration and intensity of support: 4 weeks; participants received two messages a day during weeks 1 and 4, and up to three a day during weeks 2 and 3.</p><p>Pharmacotherapy: None</p>",<p>Definition of abstinence: 7 day point prevalence</p><p>Longest follow-up: 6 months</p><p>Biochemical validation: NicAlert semi-quantitative strips &lt; 10 ng/mL</p>,<p>All authors declare no conflict of interests.</p>,<p>Not reported</p>,
Patel 2020,2020,PUB,26717891,"<p>Study type: RCT</p><p>Study registration: Not reported</p><p>Setting: India, Community (Rural)</p><p>Study dates: Not reported</p><p>Recruitment method: Oral screening.</p>","<p>Participants: 12-18 year-olds, community residents (N = 72, Age-range = 12-18 years)</p><p>Smokeless tobacco product: Scented tobacco mixture (Raag/Paan Villas), Betel nut mixture (Karamchand/Rajnigandha), Zarda</p><p>Proportion using combustible tobacco: Not reported</p><p>Proportion using products containing areca or betel: 14.5%</p>","<p>Intervention 1: Group motivational lecture on the risks of tobacco use, using audio-visual aids.&nbsp;</p><p>Provider: Primary investigator</p><p>Duration and intensity of support: 1 face-to-face session.</p><p>Pharmacotherapy: None</p><p>&nbsp;</p><p>Intervention 2: Individuliased patient-centred motivational counselling, with counselling for parents on risks of tobacco.</p><p>Provider: Primary investigator</p><p>Duration and intensity of support: 1 face-to-face session.</p><p>Pharmacotherapy: None</p>",<p>Definition of abstinence: Not reported</p><p>Longest follow-up: 9 months</p><p>Biochemical validation: Not done</p>,<p>There are no conflicts of interest.</p>,<p>Nil</p>,
Patten 2014,2014,PUB,26717893,"<p>Study type: Cluster RCT</p><p>Study registration: Not reported</p><p>Setting: USA, Community</p><p>Study dates: Not reported</p><p>Recruitment method: Flyers at community venues.</p>","<p>Participants: 12-17 year-olds, community residents (N = 68, Avg. age = 14.4 years, 53.0% Female)</p><p>Smokeless tobacco product: Alaskan Iqmik, Commercial chew</p><p>Proportion using combustible tobacco: Not reported</p><p>Proportion using products containing areca or betel: Not reported</p>","<p>Intervention 1: Brief advice along with &nbsp;self-help pamphlets, reading materials, or a referral.&nbsp;</p><p>Provider: Not reported</p><p>Duration and intensity of support: 1 face-to-face session.</p><p>Pharmacotherapy: None</p><p>&nbsp;</p><p>Intervention 2: Group counselling program.</p><p>Provider: Three to six trained counsellors staffed each program, depending on the group size. Six teen advisors (three males and three females) and three elder speakers (two males and one female) also attended the program.</p><p>Duration and intensity of support: Group intervention program was held on a weekend with two overnight stays and scheduled within 1 month of study enrollment. Duration of counselling was 8 hours total.&nbsp;</p><p>Pharmacotherapy: None</p>",<p>Definition of abstinence: 7 day point prevalence</p><p>Longest follow-up: 6 months</p><p>Biochemical validation: Salivary cotinine &lt;15 ng/ml</p>,<p>None declared.</p>,<p>National Institutes of Health and National Institute on Drug Abuse (R01 DA025156).</p>,
Rasool 2024,2024,PUB,26717895,"<p>Study type: RCT</p><p>Study registration: ISRCTN18072109</p><p>Setting: Pakistan, dental hospitals</p><p>Study dates: 2022-2023</p><p>Recruitment method: participants identified by dentists during initial oral examination, discussion and invitation to join study made by study team.</p>","<p>Participants: Patients attending one of three specialist outpatient clinics (N = 100; mean age = 41.3 years; 1 (1%) female; motivation not reported; average pouches weekly = 5.7, average daily frequency = 17.0; FTND-ST mean = 6.1)</p><p>Smokeless tobacco product: Naswar</p><p>Proportion using combustible tobacco: 20% smoking cigarettes occasionally</p><p>Proportion using products containing areca or betel: Not reported</p>","<p>Intevervention: BISCA ('behaviour support for ST users of South Asian origin'). Three sessions delivered face-to-face by trained dentists over three weeks. Duration could be up to 2 hours, but actual reported total duration under 1 hour.</p><p>Control: written self-help material - booklet provided by trained dentist</p>",<p>Definition of abstinence: Not reported</p><p>Longest follow-up: 6 months</p><p>Biochemical validation: saliva cotinine - cutoff not stated</p>,"<p>""The authors affirm that they have no competing interests""</p>","<p>""Funded by a 'faculty research grant', Khyber Medical University, Pakistan.""</p>",
Sarkar 2017,2017,PUB,26717898,"<p>Study type: Cluster RCT</p><p>Study registration: ISRCTCN23362894</p><p>Setting: India, Community (Low-income)</p><p>Study dates: 2012-2013</p><p>Recruitment method: Not reported</p>","<p>Participants: Adults, residents of selected low-income communities (N = 1213, Avg. age = 46.3 years, 20.3% Female)</p><p>Smokeless tobacco product: Not reported</p><p>Proportion using combustible tobacco: 22.3%</p><p>Proportion using products containing areca or betel: Not reported</p>","<p>Intervention 1: Very brief quit advice, providing verbal information about the harmful effects of tobacco use and advice to stop tobacco use.</p><p>Provider: Not reported</p><p>Duration and intensity of support: 1 face-to-face session (lasted on average 1 min).</p><p>Pharmacotherapy: None</p><p>&nbsp;</p><p>Intervention 2: Yogic breathing exercise and very brief quit advice. Two breathing exercises, ‘Kapalbhati’ (normal deep inhalation-forceful exhalation) and ‘Anulom vilom’ (alternate nostril breathing), were chosen.</p><p>Provider: &nbsp;A physician and a community health worker trained and initially supervised by a medical graduate researcher.</p><p>Duration and intensity of support: 1 face-to-face session of tobacco quit advice (average 15 min), and short training in two yogic breathing exercises.</p><p>Pharmacotherapy: None</p>",<p>Definition of abstinence: 7 day point prevalence and sustained</p><p>Longest follow-up: 6 months</p><p>Biochemical validation: Salivary cotinine &lt;20 ng/ml</p>,"<p>LS reports personal fees from pharmaceutical companies that make smoking cessation products and grants from Pfizer, outside the submitted work. RW reports grants and personal fees from companies that develop and manufacture smoking cessation medications, outside the submitted work; in<br>addition, he has a dormant patent ‘Nicotine cannon’ (novel nicotine delivery device) issued.</p>","<p>Wellcome Trust, UK Capacity Strengthening Strategic award to Public Health Foundation of India (PHFI) and a consortium of UK Universities (Award no 6936), with additional funding from Cancer Research UK (C1417/A14135) and UK’s National Centre for Smoking Cessation and Training.&nbsp;</p>",
Savant 2013,2013,PUB,26717902,"<p>Study type: RCT</p><p>Study registration: Not reported</p><p>Setting: India, Workplace</p><p>Study dates: Not reported</p><p>Recruitment method: Not reported</p>","<p>Participants: Industrial workers (N = 150, Age-range = 18-60 years)</p><p>Smokeless tobacco product: Chewing tobacco</p><p>Proportion using combustible tobacco: 48.0%</p><p>Proportion using products containing areca or betel: Not reported</p>","<p>Intervention 1: Brief advice in a clear, strong and personalized manner to quit tobacco consumption.</p><p>Provider: Dentist</p><p>Duration and intensity of support: 1 face-to-face session (10-15 min)</p><p>Pharmacotherapy: None</p><p>&nbsp;</p><p>Intervention 2: Group counseling consisting 6-8 participants.</p><p>Provider: Dentist</p><p>Duration and intensity of support: 5x45 minute face-to-face sessions over 6 months.</p><p>Pharmacotherapy: None</p><p>&nbsp;</p><p>Intervention 3: Individual counselling along with telephonic support for participants to call up the counsellor if they experienced problems in quitting.</p><p>Provider: Dentist</p><p>Duration and intensity of support: 5x45 minute face-to-face sessions over 6 months + &nbsp;additional phone-based counselling (when necessary).</p><p>Pharmacotherapy: None</p>",<p>Definition of abstinence: Not reported</p><p>Longest follow-up: 6 months</p><p>Biochemical validation: Cotinine (cutoffs not provided)&nbsp;</p>,<p>Not reported</p>,<p>Not reported</p>,
Schiller 2012,2012,PUB,26717904,"<p>Study type: RCT</p><p>Study registration: NCT00218296</p><p>Setting: USA, Community</p><p>Study dates: 2006-2009</p><p>Recruitment method: Advertisements on television, radio or in metropolitan and campus newspapers.</p>","<p>Participants: Adults, community residents (N = 332, Avg. age = 34.8 years, 0.3% Female)</p><p>Smokeless tobacco product: Snuff</p><p>Proportion using combustible tobacco: 0%</p><p>Proportion using products containing areca or betel: Not reported</p>","<p>Intervention 1: Immediate cessation: Setting an immediate quit date and receiving 2 weeks nicotine patch and behavioral counseling during the intervention period. A self‐help manual was also provided.</p><p>Provider: Unclear</p><p>Duration and intensity of support: 1 face-to-face session + 2 weeks nicotine patch + 1 phone counselling (10-15 min per session).</p><p>Pharmacotherapy: 21mg Nicotine Patch for 2 weeks.</p><p>&nbsp;</p><p>Intervention 2: Reduction: Counselling and instructions to reduce tobacco use by 50%, then 75% over 6 weeks prior to quit date, using nicotine lozenge or brand switching resulting in reduced nicotine exposure.&nbsp;</p><p>Provider: Unclear</p><p>Duration and intensity of support: 1 face-to-face session + choice of either 4mg nicotine lozenge or brand switching + 1 phone counselling (10-15 min per session).</p><p>Pharmacotherapy: &nbsp;Choice of 4mg nicotine lozenge or brand switching.</p>",<p>Definition of abstinence: 7 day point prevalence and sustained</p><p>Longest follow-up: 26 weeks</p><p>Biochemical validation: Urine cotinine &lt;20 ng/ml and anatabine &lt;2 ng/ml</p>,<p>Dorothy Hatsukami had received a grant from Nabi Biopharmaceutical to conduct a clinical trial on the nicotine vaccine for smoking &nbsp;cessation.</p>,"<p>National Institute on Drug Abuse of the National Institutes of Health (R01DA14404), and the National Heart, Lung and Blood Institute of the National Institutes of Health (T32HL007741).</p>",
Severson 2000,2000,PUB,26717908,"<p>Study type: RCT</p><p>Study registration: Not reported</p><p>Setting: USA, Community (Rural)</p><p>Study dates: Not reported</p><p>Recruitment method: Advertisements and other publicity in print and electronic media.</p>","<p>Participants: Adults, community residents (N = 198, Avg. age = 38.9 years, 2.0% Female)</p><p>Smokeless tobacco product: US tins/pouches</p><p>Proportion using combustible tobacco: 4.0%</p><p>Proportion using products containing areca or betel: Not reported</p>","<p>Intervention 1: Self-help manual (Third edition of 'Enough Snuff: A guide for quitting ST) mailed, a copy of a video to help patients quit ST, and phone-based counsellor support.&nbsp;</p><p>Provider: Trained tobacco cessation counsellors.&nbsp;</p><p>Duration and intensity of support: The video was 16 min long, and the manual was 50 pages.&nbsp;</p><p>Pharmacotherapy: None</p><p>&nbsp;</p><p>Intervention 2: Life-sign intervention: A small computer that promtped users to reduce the frequency and duration of tobacco use until elimination, with phone-based counsellor support.</p><p>Provider: Trained tobacco cessation counsellors.&nbsp;</p><p>Duration and intensity of support: 10-32 days.</p><p>Pharmacotherapy: None</p>",<p>Definition of abstinence: 7 day point prevalence</p><p>Longest follow-up: 6 months</p><p>Biochemical validation: Not done</p>,<p>Not reported</p>,<p>Not reported</p>,
Severson 2007,2007,PUB,26717911,"<p>Study type: RCT</p><p>Study registration: Not reported</p><p>Setting: USA, Community (Rural)</p><p>Study dates: Not reported</p><p>Recruitment method: News stories and announcements in print and broadcast media.</p>","<p>Participants: 15 years and older, community residents (N = 1069, Avg. age = 38.3 years in assisted self-help and 38.8 years in manual-only, 3.0% Female)</p><p>Smokeless tobacco product: Not reported</p><p>Proportion using combustible tobacco: 7.0% in assisted self-help and 4.0% in manual-only&nbsp;</p><p>Proportion using products containing areca or betel: Not reported</p>","<p>Intervention 1: Self-help manual 'Enough Snuff: A Guide for Quitting Smokeless Tobacco, fourth edition (Severson, 1997)', a 60-page quitting guide mailed.</p><p>Provider: N/A</p><p>Duration and intensity of support: N/A</p><p>Pharmacotherapy: None</p><p>&nbsp;</p><p>Intervention 2: Asssisted self-help with a mailed copy of the Enough Snuff Manual, a 20 min video designed to accompany the manual, and two supportive phone calls. &nbsp;</p><p>Provider: Trained tobacco cessation counsellors.&nbsp;</p><p>Duration and intensity of support: 2 phone-based contacts.</p><p>Pharmacotherapy: None</p>",<p>Definition of abstinence: 7 day point prevalence</p><p>Longest follow-up: 18 months</p><p>Biochemical validation: Not done</p>,<p>Not reported</p>,<p>National Cancer Institute (Grant CA 60586).</p>,
Severson 2008,2008,PUB,26717918,"<p>Study type: RCT</p><p>Study registration: Not reported</p><p>Setting: USA and Canada, Community (Web-based)</p><p>Study dates: Not reported</p><p>Recruitment method: News releases to print and broadcast media, paid advertising, links on other websites, direct mailing to ST users and targeted mailling to health care and tobacco control professionals.</p>","<p>Participants: Adults, community residents (N = 2523, Avg. age = 36.8 years, 2.5% Female)</p><p>Smokeless tobacco product: North American ST</p><p>Proportion using combustible tobacco: 4.4%</p><p>Proportion using products containing areca or betel: Not reported</p>","<p>Intervention 1: Website (basic) designed to provide ST cessation content in a static, textual format. &nbsp;</p><p>Provider: Web-based delivery.</p><p>Duration and intensity of support: N/A</p><p>Pharmacotherapy: None</p><p>&nbsp;</p><p>Intervention 2: Website (enhanced) designed to be a personal qutting assistant, with guided interactive programs to create a tailored quit plan, stream video, and offer wider range of resources.&nbsp;</p><p>Provider: Web-based delivery.</p><p>Duration and intensity of support: N/A</p><p>Pharmacotherapy: None</p>",<p>Definition of abstinence: 7 day point prevalence</p><p>Longest follow-up: 6 months</p><p>Biochemical validation: Not done</p>,<p>Not reported</p>,<p>National Cancer Institute (Grant R01-CA84225).</p>,
Severson 2009,2009,PUB,26717929,"<p>Study type: RCT</p><p>Study registration: Not reported</p><p>Setting: USA, Dental practice (Military)</p><p>Study dates: 2003-2005</p><p>Recruitment method: Military personnel contacted at their annual dental examination.</p>","<p>Participants: Military personnel attending military dental clinics (N = 785, Avg. age = 30.4 years, 0.01% Female)</p><p>Smokeless tobacco product: North American ST</p><p>Proportion using combustible tobacco: 20.2%</p><p>Proportion using products containing areca or betel: Not reported</p>","<p>Intervention 1: Brief advice at dental check up and cessation clinic referral.</p><p>Provider: Dental provider.</p><p>Duration and intensity of support: 1 session</p><p>Pharmacotherapy: None</p><p>&nbsp;</p><p>Intervention 2: Self-help guidebook, video-based ST cessation program and three brief counselling sessions.</p><p>Provider: Trained counsellors.</p><p>Duration and intensity of support: 3 phone-based counselling sessions, placed at 1 week after dental examination, 3 weeks after being mailed the self-help quitting materials, and few days after the quit date.&nbsp;</p><p>Pharmacotherapy: None</p>",<p>Definition of abstinence: 30 day point prevalence and sustained</p><p>Longest follow-up: 6 months</p><p>Biochemical validation: Not done</p>,<p>The views expresssed are those of the authors and are not the official plicy of the US dept of Defense or US Airforce.</p>,<p>Congressionally directed Medical research program's peer review medical research program to HHS (DAMD17-02-2-0).</p>,
Severson 2015,2015,PUB,26717932,"<p>Study type: RCT</p><p>Study registration: NCT01341938</p><p>Setting: USA, Community</p><p>Study dates: 2011-2013</p><p>Recruitment method: Online (Google AdWords) campaign.</p>","<p>Participants: Adults, community residents (N = 1067, Avg. age = 35.8 years, 2.4% Female)</p><p>Smokeless tobacco product: Not reported</p><p>Proportion using combustible tobacco: 6.3%</p><p>Proportion using products containing areca or betel: Not reported</p>","<p>Intervention 1: Tobacco cessation counselling intended to reinforce and personalize the procedures described in the self-help materials.</p><p>Provider: Researchers experienced in motivational interviewing.</p><p>Duration and intensity of support: 3 proactive phone-based counselling sessions - Call #1 was 1 week after randomization, Call #2 was 2–3 days after participant’s quit date, Call #3 was 14–21 days following call #2.</p><p>Pharmacotherapy: None</p><p>&nbsp;</p><p>Intervention 2: NRT</p><p>Provider: N/A</p><p>Duration and intensity of support: N/A</p><p>Pharmacotherapy: 3 boxes of Nicorette® Mini-Lozenges (4 mg): 81 lozenges/box. Tapered usage over time: weeks 1–6 = 1 lozenge every 1 to 2 hour, weeks 7–9 = 1 lozenge every 2–4 hour, and weeks 10–12 = 1 lozenge every 4–8hr. Additional boxes could be requested.&nbsp;</p><p>&nbsp;</p><p>Intervention 3: Tobacco cessation counselling intended to reinforce and personalize the procedures described in the self-help materials + NRT.</p><p>Provider: Researchers experienced in motivational interviewing.</p><p>Duration and intensity of support: 3 proactive phone-based counselling sessions - Call #1 was 1 week after randomization, Call #2 was 2–3 days after participant’s quit date, Call #3 was 14–21 days following call #2.</p><p>Pharmacotherapy: 3 boxes of Nicorette® Mini-Lozenges (4 mg): 81 lozenges/box. Tapered usage over time: weeks 1–6 = 1 lozenge every 1 to 2 hour, weeks 7–9 = 1 lozenge every 2–4hr, and weeks 10–12 = 1 lozenge every 4–8hr. Additional boxes could be requested.&nbsp;</p>",<p>Definition of abstinence: 7 day point prevalence</p><p>Longest follow-up: 6 months</p><p>Biochemical validation: Not done</p>,"<p>JOE has received personal fees from GlaxoSmithKline and has received<br>research support from Pfizer, Orexigen, and JHP outside of this study.<br>GlaxoSmithKline provided the nicotine lozenges for the study, but it had no<br>role in the conduct of the study or in the preparation, review, approval of the manuscript, and decision to submit the manuscript for publication.</p>",<p>National Cancer Institute of the National Institutes of Health (Grant R01-CA142952).</p>,
Siddiqui 2024,2024,PUB,26717936,"<p>Study type: RCT</p><p>Study registration: ISRCTN65109397</p><p>Setting: Bangladesh, Pakistan and India; primary care</p><p>Study dates: 2019-2021</p><p>Recruitment method: ""Individuals seeking health-care and those attending clinics followingcommunity mobilization (public announcements, brochures and leaf-lets promoting the trial) were screened by a trained researcher using a checklist""&nbsp;</p>","<p>Participants: 264 adult daily ST users willing to make a quit attempt within 30 days (mean age 35; 46.9% female; 93% reported ""a lot"" of motivation to quit; mean FTND 5.3)</p><p>Smokeless tobacco product: tobacco paan (60.6%), mawa (24.2%), gutka (7.9%), khaini (7.2%), paan masala (6.4%), gul (6.4%), zarda (3.8%), naswar (4.2%)</p><p>Proportion using combustible tobacco: none - dual users excluded</p><p>Proportion using products containing areca or betel: not reported</p>","<p>Intervention 1: Very brief advice based on the 3As (Ask, Advise, Act) approach plus a self-help leaflet containing information on quit planning<br>Intervention 2: Behavioural intervention for smokeless tobaccocessation in adults (BISCA), up to eight sessions delivered face-to-face and then by telephone by trained profesiosnals, total duration could last over 3 hours<br>Intervention 3: NRT gum; 4 mg or 6 mg for 8 weeks<br>Intervention 4: Both BISCA and NRT</p>",<p>Definition of abstinence: continuous from quit date</p><p>Longest follow-up: 6 months</p><p>Biochemical validation: saliva cotinine (cut-off &lt; 15 ng/ml)</p>,"<p>""The authors have no conflicts of interest to declare.""</p>","<p>""The ASTRA cessation trial was funded by the National Institute ofHealth and Care Research (UK) (programme ref. 17/63/76/GlobalHealth Research Groups). L.B.’s time was partly funded by theEconomic and Social Research Council via Behavioural Research UK(grant ref. ES/Y001044/1)""</p>",
Stevens 1995,1995,PUB,26717939,"<p>Study type: RCT</p><p>Study registration: Not reported</p><p>Setting: USA, Dental practice</p><p>Study dates: Not reported</p><p>Recruitment method: Participants attending routine dental care visits.</p>","<p>Participants: 15 years and older, routine dental hygiene visit (N = 576, Avg. age = Not reported, 100% Male)</p><p>Smokeless tobacco product: Not reported</p><p>Proportion using combustible tobacco: 30.0%</p><p>Proportion using products containing areca or betel: Not reported</p>","<p>Intervention 1: Usual care - Patients may or may not have received advice to quit, depending on personal practice habits of dental care providers.</p><p>Provider: N/A</p><p>Duration and intensity of support: N/A</p><p>Pharmacotherapy: None</p><p>&nbsp;</p><p>Intervention 2: Oral examination with feedback, advice to quit, educational 9-minute video; a quit date was set and self-help booklet and 24-hour helpline provided along with a quit kit containing oral substitutes.&nbsp;</p><p>Provider: Dentist or dental hygienist.</p><p>Duration and intensity of support: 1 face-to-face contact, with phone-based and mail-based support.</p><p>Pharmacotherapy: None</p>",<p>Definition of abstinence: Not reported</p><p>Longest follow-up: 12 months</p><p>Biochemical validation: saliva samples were collected but not analysed&nbsp;</p>,<p>Not reported</p>,<p>National Cancer Institute (Grant Number P01 CA 44648).</p>,
Stotts 2003,2003,PUB,26717941,"<p>Study type: RCT</p><p>Study registration: Not reported</p><p>Setting: USA, High school</p><p>Study dates: Not reported</p><p>Recruitment method: Radio and online advertisements, school-based awareness sessions.</p>","<p>Participants: 14-19 year-olds (N = 303, Avg. age = 17 years, 100% Male)</p><p>Smokeless tobacco product: Chewing tobacco or Snuff</p><p>Proportion using combustible tobacco: Not reported</p><p>Proportion using products containing areca or betel: Not reported</p>","<p>Intervention 1: Brief advice only.</p><p>Provider: Not reported</p><p>Duration and intensity of support: 3-5 min brief counselling session and 5-10 min phone-based session 2 weeks later.</p><p>Pharmacotherapy: None</p><p>&nbsp;</p><p>Intervention 2: Behavioural intervention sessions, adapted to be age-appropriate with placebo patch.&nbsp;</p><p>Provider: Health educator</p><p>Duration and intensity of support: 6 weeks phone-based sessions, 50 minutes each.</p><p>Pharmacotherapy: Placebo patch</p><p>&nbsp;</p><p>Intervention 3: Behavioural intervention sessions, adapted to be age-appropriate with NRT patch.&nbsp;</p><p>Provider: Health educator</p><p>Duration and intensity of support: &nbsp;6 weeks phone-based sessions, 50 minutes each.</p><p>Pharmacotherapy: Active NRT patch (14 mg x 3 weeks, 7 mg x 3 weeks for light/moderate users. 21 mg x 2 weeks, 14 mg x 2 weeks, 7 mg x 2 weeks for heavy users).</p>",<p>Definition of abstinence: 30 day point prevalence</p><p>Longest follow-up: 12 months</p><p>Biochemical validation: Salivary cotinine (cutoffs not provided)</p>,<p>Not reported</p>,<p>National Cancer Institute (Grant Number R91 CA76969-03).</p>,
Tas 2020,2020,PUB,26717944,"<p>Study type: RCT</p><p>Study registration: Not reported</p><p>Setting: Turkey, High school</p><p>Study dates: Not reported</p><p>Recruitment method: Not reported</p>","<p>Participants: High school students who use ST (N = 90, Avg. age and Gender = Not reported)</p><p>Smokeless tobacco product: Not reported</p><p>Proportion using combustible tobacco: Not reported</p><p>Proportion using products containing areca or betel: Not reported</p>","<p>Intervention 1: Waitlist control, provided with educational information and brochures related to ST in the 12th month of the study.&nbsp;</p><p>Provider: N/A</p><p>Duration and intensity of support: N/A</p><p>Pharmacotherapy: None</p><p>&nbsp;</p><p>Intervention 2: A Motivational Interviewing (MI) program and information brochures.</p><p>Provider: Unclear</p><p>Duration and intensity of support: 5 face-to-face MI sessions at months 1-4. Sessions lasted 40 min on average for students at the stage of precontemplation, and 25–30 min on average for students at the stage of contemplation, preparation and maintenance. Phone interviews conducted at months 5-8 for 3–5 minutes in order to motivate.&nbsp;</p><p>Pharmacotherapy: None</p>",<p>Definition of abstinence: Not reported</p><p>Longest follow-up: 12 months</p><p>Biochemical validation: Not done</p>,<p>Not reported</p>,<p>Not reported</p>,
Virtanen 2015,2015,PUB,26717946,"<p>Study type: Cluster RCT</p><p>Study registration: ISRCTN50627997</p><p>Setting: Sweden, Dental practice</p><p>Study dates: 2012-2013</p><p>Recruitment method: Eligible dental practices identified and recruited via the head of each clinic, or the healthcare district managers.</p>","<p>Participants: Adults seeking dental care (N = 467, Avg. age = 45.6 years, 36.6% Female)</p><p>Smokeless tobacco product: Snus</p><p>Proportion using combustible tobacco: 8.9%</p><p>Proportion using products containing areca or betel: Not reported</p>",<p>Intervention 1: Assistance for tobacco cessation (face-to-face information on the consequences of tobacco on oral health).</p><p>Provider: Dentist or dental hygienist.</p><p>Duration and intensity of support: Not reported</p><p>Pharmacotherapy: None</p><p>&nbsp;</p><p>Intervention 2: A structured very brief advice based on the 5 A's.</p><p>Provider: Dentist or dental hygienist.</p><p>Duration and intensity of support: One face-to-face session of 5 minutes duration.</p><p>Pharmacotherapy: None</p>,<p>Definition of abstinence: 7 day point prevalence and sustained</p><p>Longest follow-up: 6 months</p><p>Biochemical validation: Not done</p>,<p>The authors declare that there are no conflicts of interest. No financial disclosures were reported by the authors of this paper.</p>,<p>National Board of Health and Welfare (Contract Grant Number 2.4-43860/2011).</p>,
Walsh 1999,1999,PUB,26717949,"<p>Study type: Cluster RCT</p><p>Study registration: Not reported</p><p>Setting: USA, College</p><p>Study dates: 1990-1993</p><p>Recruitment method: Colleges with football and baseball teams enrolled through athletic directors/coaches; athletes recruited through team meetings.</p>","<p>Participants: Athletes from football and baseball teams (N = 360, Avg. age = Not reported, 100% Male)</p><p>Smokeless tobacco product: Chew/dip</p><p>Proportion using combustible tobacco: &lt; 2.0%</p><p>Proportion using products containing areca or betel: Not reported</p>","<p>Intervention 1: No treatment.</p><p>Provider: N/A</p><p>Duration and intensity of support: N/A</p><p>Pharmacotherapy: None</p><p>&nbsp;</p><p>Intervention 2: Athletic team-based cessation program, consisting of oral examination, counselling and advice to quit, with nicotine gum.&nbsp;</p><p>Provider: Dentist, dental hygienist, non-ST-using peers.</p><p>Duration and intensity of support: 15-20 min one-time face-to-face interaction with 5-10 min phone-based contact on the quit date and 1 month.&nbsp;</p><p>Pharmacotherapy: Nicotine gum (2mg) was also offered to mitigate withdrawal symtpoms.&nbsp;</p>",<p>Definition of abstinence: 30 day point prevalence</p><p>Longest follow-up: 12 months</p><p>Biochemical validation: Salivary cotinine (cutoffs not provided)</p>,<p>Not reported</p>,<p>Tobacco Surtax Fund of the State of California through the Tobacco-Related Disease Research Program of the University of California.</p>,
Walsh 2010,2010,PUB,26717952,"<p>Study type: Cluster RCT</p><p>Study registration: Not reported</p><p>Setting: USA, High school (Rural)</p><p>Study dates: 2000-2005</p><p>Recruitment method: Eligible schools enrolled by contacting the principal; individual subjects recruited via cover letter and consent form included in the student registration packs.</p>","<p>Participants: 17 years or younger, high school students (N = 4731, Avg. age = Not reported, 100% Male)</p><p>Smokeless tobacco product: Chew/dip</p><p>Proportion using combustible tobacco: 6.0%</p><p>Proportion using products containing areca or betel: Not reported</p>","<p>Intervention 1: No treatment.</p><p>Provider: N/A</p><p>Duration and intensity of support: N/A</p><p>Pharmacotherapy: None</p><p>&nbsp;</p><p>Intervention 2: A peer-led educational session, an oral examination with feedback, and three nurse-led group cessation counselling sessions.</p><p>Provider: School nurse and student peers.</p><p>Duration and intensity of support: 3-4 weeks (3 once a week 1-hour face-to-face sessions following 45 min peer session and oral exam).</p><p>Pharmacotherapy: None</p>",<p>Definition of abstinence: 30 day point prevalence&nbsp;</p><p>Longest follow-up: 12 months</p><p>Biochemical validation: Not done</p>,<p>None declared.</p>,"<p>National Institute of Dental and Craniofacial Research, National Institutes of Health (Grant Number US DHHS NIH/NIDCR P60DE13058).</p>",
